摘要
目的研究液基薄层细胞学(TCT)联合高危型人乳头瘤病毒(HPV)-DNA及端粒酶检测在宫颈癌前病变评估中的应用价值。方法选取2016年2-10月该院女性患者668例同时进行TCT、HPV-DNA及端粒酶的检测,并对其中1项阳性者进行阴道镜下病理组织活检。结果 TCT、HPV-DNA和端粒酶检测的阳性率均明显小于病理学检查阳性率,差异有统计学意义(P<0.05);3项指标联合检测的敏感度为90.22%,特异度为85.45%,阴性预测值为83.04%。结论 TCT、HPV-DNA及端粒酶检测均有一定局限性,但上述方法联合应用将大大提高检出率,有利于宫颈癌的早期诊断。
Objective To investigate the application value of union detection of TCT,HPV-DNA and telomerase detection in screening for precancerous lesions.Methods Clinical data of 668 women patients in the Hospital from February to October in2016.The patients of TCT positive,HPV-DNA positive and telomerase detection positive received pathological biopsy under colposcope.Results The positive rates of the 3 tests were all lower than the rates shown in the pathological examinations,the difference was statistically significant（P〈0.05）.The sensitivity in the combined detection of TCT,HPV and telomerase was 90.22%,the specificity was 85.45%,the negative prediction value was 83.04%.Conclusion The TCT,HPV-DNA and telomerase detection 3 tests have their limitations.The combining of them can significantly enhance positive rate for earlier and more accurate detection.
出处
《检验医学与临床》
CAS
2017年第21期3193-3194,共2页
Laboratory Medicine and Clinic
